|Mr. Martin Babler||Pres, CEO & Director||790.33k||N/A||1965|
|Ms. Stefani A. Wolff||Chief Devel. Officer||494.23k||N/A||1962|
|Dr. Dolca Thomas M.D.||Chief Medical Officer||366.83k||N/A||1971|
|Mr. Christopher Y. Chai||Chief Financial Officer||N/A||N/A||1967|
|Dr. David M. Goldstein||Chief Scientific Officer||N/A||N/A||1966|
Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.
Principia Biopharma Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 8; Compensation: 9.